Phase 2

Portfolio Company Vedanta Announces Promising Phase 2 Trial Results

Blog / By

By Sal Daher, CFA Vedanta Biosciences announced October 5th, 2021 that its experimental therapy VE303 reduces the likelihood of recurrence of C. diff. by more than 80%. BARDA exercises $23.8 million to fund Phase 3 clinical trials starting in 2022. Heres a link to the press release: https://www.businesswire.com/news/home/20211005005154/en/PureTech-Founded-Entity-Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA

PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA

Biotech Hub / By

High-dose VE303 in Phase 2 trial achieved primary endpoint, with 31.7% absolute risk reduction in rate of recurrence (or a greater than 80% reduction in the odds of a recurrence) at 8 weeks when compared with placebo Represents most advanced clinical trial of a rationally defined bacterial consortium candidate BARDA exercises $23.8 million option to …

PureTech Founded Entity Vedanta Announces Positive Topline Phase 2 Data for VE303 in High-Risk C. difficile Infection and Exercise of $23.8 Million Option by BARDA Read More »